Literature DB >> 33303993

Why remission is not enough: underlying disease mechanisms in RA that prevent cure.

Georg Schett1,2, Yoshiya Tanaka3, John D Isaacs4,5.   

Abstract

Cure is the aspirational aim for the treatment of all diseases, including chronic inflammatory conditions such as rheumatoid arthritis (RA); however, it has only been during the twenty-first century that remission, let alone cure, has been a regularly achievable target in RA. Little research has been carried out on how to cure RA, and the term 'cure' still requires definition for this disease. Even now, achieving a cure seems to be a rare occurrence among individuals with RA. Therefore, this Review is aimed at addressing the obstacles to the achievement of cure in RA. The differences between remission and cure in RA are first defined, followed by a discussion of the underlying factors (referred to as drivers) that prevent the achievement of cure in RA by triggering sustained immune activation and effector cytokine production. Such drivers include adaptive immune system activation, mesenchymal tissue priming and so-called 'remote' (non-immune and non-articular) factors. Strategies to target these drivers are also presented, with an emphasis on the development of strategies that could complement currently used cytokine inhibition and thereby improve the likelihood of curing RA.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33303993     DOI: 10.1038/s41584-020-00543-5

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN: 1759-4790            Impact factor:   20.543


  86 in total

1.  Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states.

Authors:  Daniel Aletaha; Michael M Ward; Klaus P Machold; Valerie P K Nell; Tanja Stamm; Josef S Smolen
Journal:  Arthritis Rheum       Date:  2005-09

2.  Defining remission in rheumatoid arthritis.

Authors:  David Felson
Journal:  Ann Rheum Dis       Date:  2012-04       Impact factor: 19.103

3.  American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials.

Authors:  David T Felson; Josef S Smolen; George Wells; Bin Zhang; Lilian H D van Tuyl; Julia Funovits; Daniel Aletaha; Cornelia F Allaart; Joan Bathon; Stefano Bombardieri; Peter Brooks; Andrew Brown; Marco Matucci-Cerinic; Hyon Choi; Bernard Combe; Maarten de Wit; Maxime Dougados; Paul Emery; Daniel Furst; Juan Gomez-Reino; Gillian Hawker; Edward Keystone; Dinesh Khanna; John Kirwan; Tore K Kvien; Robert Landewé; Joachim Listing; Kaleb Michaud; Emilio Martin-Mola; Pamela Montie; Theodore Pincus; Pamela Richards; Jeffrey N Siegel; Lee S Simon; Tuulikki Sokka; Vibeke Strand; Peter Tugwell; Alan Tyndall; Desirée van der Heijde; Suzan Verstappen; Barbara White; Frederick Wolfe; Angela Zink; Maarten Boers
Journal:  Ann Rheum Dis       Date:  2011-03       Impact factor: 19.103

4.  A simplified disease activity index for rheumatoid arthritis for use in clinical practice.

Authors:  J S Smolen; F C Breedveld; M H Schiff; J R Kalden; P Emery; G Eberl; P L van Riel; P Tugwell
Journal:  Rheumatology (Oxford)       Date:  2003-02       Impact factor: 7.580

5.  Time trends in disease activity, response and remission rates in rheumatoid arthritis during the past decade: results from the NOR-DMARD study 2000-2010.

Authors:  Anna-Birgitte Aga; Elisabeth Lie; Till Uhlig; Inge Christoffer Olsen; Ada Wierød; Synøve Kalstad; Erik Rødevand; Knut Mikkelsen; Tore K Kvien; Espen A Haavardsholm
Journal:  Ann Rheum Dis       Date:  2013-11-27       Impact factor: 19.103

6.  Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria.

Authors:  J Fransen; M C W Creemers; P L C M Van Riel
Journal:  Rheumatology (Oxford)       Date:  2004-07-06       Impact factor: 7.580

Review 7.  Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions.

Authors:  Georg Schett; Paul Emery; Yoshiya Tanaka; Gerd Burmester; David S Pisetsky; Esperanza Naredo; Bruno Fautrel; Ronald van Vollenhoven
Journal:  Ann Rheum Dis       Date:  2016-06-03       Impact factor: 19.103

8.  Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial.

Authors:  Johannes W J Bijlsma; Paco M J Welsing; Thasia G Woodworth; Leonie M Middelink; Attila Pethö-Schramm; Corrado Bernasconi; Michelle E A Borm; Cornelis H Wortel; Evert Jan Ter Borg; Z Nazira Jahangier; Willemijn H van der Laan; George A W Bruyn; Paul Baudoin; Siska Wijngaarden; Petra A J M Vos; Reinhard Bos; Mirian J F Starmans; Eduard N Griep; Joanna R M Griep-Wentink; Cornelia F Allaart; Anton H M Heurkens; Xavier M Teitsma; Janneke Tekstra; Anne Carien A Marijnissen; Floris P J Lafeber; Johannes W G Jacobs
Journal:  Lancet       Date:  2016-06-07       Impact factor: 79.321

Review 9.  Pathogenetic insights from the treatment of rheumatoid arthritis.

Authors:  Iain B McInnes; Georg Schett
Journal:  Lancet       Date:  2017-06-10       Impact factor: 79.321

10.  Intensive therapy and remissions in rheumatoid arthritis: a systematic review.

Authors:  Catherine D Hughes; David L Scott; Fowzia Ibrahim
Journal:  BMC Musculoskelet Disord       Date:  2018-10-30       Impact factor: 2.362

View more
  10 in total

Review 1.  Follicular helper T cells: potential therapeutic targets in rheumatoid arthritis.

Authors:  Jian Lu; Jing Wu; Xueli Xia; Huiyong Peng; Shengjun Wang
Journal:  Cell Mol Life Sci       Date:  2021-04-20       Impact factor: 9.261

Review 2.  Alcohol Consumption in Rheumatoid Arthritis: A Path through the Immune System.

Authors:  Vugar Azizov; Mario M Zaiss
Journal:  Nutrients       Date:  2021-04-16       Impact factor: 5.717

Review 3.  Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach.

Authors:  Yoshiya Tanaka; Yiming Luo; John J O'Shea; Shingo Nakayamada
Journal:  Nat Rev Rheumatol       Date:  2022-01-05       Impact factor: 32.286

Review 4.  Synovial single-cell heterogeneity, zonation and interactions: a patchwork of effectors in arthritis.

Authors:  Barbora Schonfeldova; Kristina Zec; Irina A Udalova
Journal:  Rheumatology (Oxford)       Date:  2022-03-02       Impact factor: 7.580

Review 5.  A broad look into the future of rheumatoid arthritis.

Authors:  Johanna Mucke; Martin Krusche; Gerd R Burmester
Journal:  Ther Adv Musculoskelet Dis       Date:  2022-02-09       Impact factor: 5.346

Review 6.  Big data analyses and individual health profiling in the arena of rheumatic and musculoskeletal diseases (RMDs).

Authors:  Diederik De Cock; Elena Myasoedova; Daniel Aletaha; Paul Studenic
Journal:  Ther Adv Musculoskelet Dis       Date:  2022-06-30       Impact factor: 3.625

7.  Efficacy of Abatacept Versus Tumor Necrosis Factor Inhibitors in Anti-citrullinated Protein Antibody-Positive Patients with Rheumatoid Arthritis: Results from a Korean Nationwide Biologics Registry.

Authors:  Min Jung Kim; Sun-Kyung Lee; Sohee Oh; Hyoun-Ah Kim; Yong-Beom Park; Shin-Seok Lee; Kichul Shin
Journal:  Rheumatol Ther       Date:  2022-06-18

8.  Role of DNA dioxygenase Ten-Eleven translocation 3 (TET3) in rheumatoid arthritis progression.

Authors:  Akio Kawabe; Kaoru Yamagata; Shigeaki Kato; Kazuhisa Nakano; Kei Sakata; Yu-Ichi Tsukada; Koichiro Ohmura; Shingo Nakayamada; Yoshiya Tanaka
Journal:  Arthritis Res Ther       Date:  2022-09-16       Impact factor: 5.606

Review 9.  Recent progress in treatments of rheumatoid arthritis: an overview of developments in biologics and small molecules, and remaining unmet needs.

Authors:  Yoshiya Tanaka
Journal:  Rheumatology (Oxford)       Date:  2021-12-24       Impact factor: 7.580

10.  Mapping Autoantibodies in Children With Acute Rheumatic Fever.

Authors:  Reuben McGregor; Mei Lin Tay; Lauren H Carlton; Paulina Hanson-Manful; Jeremy M Raynes; Wasan O Forsyth; Diane T Brewster; Martin J Middleditch; Julie Bennett; William John Martin; Nigel Wilson; Polly Atatoa Carr; Michael G Baker; Nicole J Moreland
Journal:  Front Immunol       Date:  2021-07-15       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.